Pluri (NASDAQ:PLUR) Releases Quarterly Earnings Results

Pluri (NASDAQ:PLUR) issued its quarterly earnings data on Thursday. The company reported ($0.85) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.76 million for the quarter.

Pluri Stock Down 8.7%

NASDAQ PLUR traded down $0.10 on Thursday, reaching $1.09. The company had a trading volume of 18,915 shares, compared to its average volume of 68,385. The company’s fifty day moving average is $1.10 and its 200 day moving average is $2.29. Pluri has a 52-week low of $0.85 and a 52-week high of $4.87. The stock has a market capitalization of $13.81 million, a P/E ratio of -0.45 and a beta of 0.64.

Insiders Place Their Bets

In other Pluri news, Director Alexandre Weinstein Manieu bought 833,334 shares of the business’s stock in a transaction dated Friday, October 23rd. The shares were purchased at an average price of $1.50 per share, for a total transaction of $1,250,001.00. Following the purchase, the director directly owned 2,083,334 shares of the company’s stock, valued at approximately $3,125,001. This represents a 66.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 43.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Pluri

Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.